Palvella (NASDAQ: PVLA) COO sells 4,302 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin reported option exercises and share sales in the company’s stock. On May 20, 2026, she exercised stock options for 2,154 shares at $7.14 per share and 2,148 shares at $9.08 per share, acquiring 4,302 shares of common stock.
That same day, she sold a total of 4,302 common shares in open‑market transactions at weighted average prices of about $110.35, $111.30, and $111.90. The filing shows she held 0 common shares directly after these transactions. The sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on August 19, 2025, during an open trading window.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,302 shares ($475,631)
Net Sell
7 txns
Insider
Goin Kathleen
Role
Chief Operating Officer
Sold
4,302 shs ($476K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,154 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,148 | $0.00 | -- |
| Exercise | Common Stock | 2,154 | $7.14 | $15K |
| Exercise | Common Stock | 2,148 | $9.08 | $20K |
| Sale | Common Stock | 3,363 | $110.3464 | $371K |
| Sale | Common Stock | 891 | $111.2963 | $99K |
| Sale | Common Stock | 48 | $111.895 | $5K |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,781 shares (Direct, null);
Common Stock — 2,154 shares (Direct, null)
Footnotes (1)
- The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.87 to $110.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.89 to $111.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The stock option is fully vested.
Key Figures
Shares sold: 4,302 shares
Sale prices: $110.3464, $111.2963, $111.8950/share
Options exercised (7.14): 2,154 shares at $7.14/share
+4 more
7 metrics
Shares sold
4,302 shares
Total common stock sold on May 20, 2026
Sale prices
$110.3464, $111.2963, $111.8950/share
Weighted average prices for three sale entries
Options exercised (7.14)
2,154 shares at $7.14/share
Stock option exercise into common stock
Options exercised (9.08)
2,148 shares at $9.08/share
Stock option exercise into common stock
Net share change
-4,302 shares
NetBuySellShares from transaction summary (net-sell)
Shares after final sale
0 shares
Total_shares_following_transaction for last sale
Rule 10b5-1 plan adoption date
August 19, 2025
Date plan governing these trades was adopted
Key Terms
Rule 10b5-1 trading plan, material non-public information, Insider Trading Policy, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
material non-public information regulatory
"at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved..."
Material non-public information is important news about a company that hasn't been shared with the public yet, like a secret that could affect its stock price. Using this inside information to buy or sell stocks is unfair and illegal because it gives someone an unfair advantage over others who don’t have the same info.
Insider Trading Policy regulatory
"and was reviewed and approved in accordance with the Issuer's Insider Trading Policy."
A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.
weighted average price financial
"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option financial
"The stock option is fully vested."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
What stock options did Kathleen Goin exercise in Palvella Therapeutics (PVLA)?
She exercised options for 2,154 shares at an exercise price of $7.14 per share and 2,148 shares at $9.08 per share. These option exercises converted derivative positions into 4,302 shares of common stock before the same-day open-market sales.
Does Kathleen Goin still hold Palvella Therapeutics (PVLA) common stock after these transactions?
The Form 4 reports that Goin held 0 common shares directly following the final sale entry. The total_shares_following_transaction field for the last reported sale shows a balance of 0.0000 shares of Palvella Therapeutics common stock owned directly.
Were Kathleen Goin’s PVLA stock sales made under a Rule 10b5-1 trading plan?
Yes. A footnote explains the transactions were effected under a Rule 10b5-1 trading plan adopted on August 19, 2025. It states the plan was adopted during an open trading window when she was not in possession of material non-public information.
What does the weighted average price disclosure mean in the PVLA Form 4?
The filing states each reported price is a weighted average for multiple trades executed within a price range. For example, one block was sold between $109.87 and $110.82. The insider commits to provide detailed trade-by-trade prices upon request.